Evidence map›Paper›PMID 38732279›Full record

ReviewDiagnostics (Basel, Switzerland)2024

Visual Function Improvement after Plasma Exchange Therapy for Acute Optic Neuritis in Neuromyelitis Optica Spectrum Disorders: Case Series and Review.

Raluca Iancu, Ruxandra Pirvulescu, Nicoleta Anton, George Iancu, Sinziana Istrate, Mihaela Oana Romanitan, Aida Geamanu, Matei Popa Cherecheanu

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. MOGJournal of neuroinflammation · 2025
    Review
  3. Complement updates in optic neuritis.Frontiers in neurology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Raluca IancuDepartment of Ophthalmology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0001-6933-8219
Ruxandra PirvulescuDepartment of Ophthalmology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0002-7462-0929
Nicoleta AntonDepartment of Ophthalmology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
George IancuDepartment of Obstetrics-Gynecology, "Carol Davila" University of Medicine and Pharmacy, 020956 Bucharest, Romania.
Sinziana IstrateDepartment of Ophthalmology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Mihaela Oana RomanitanDepartment of Internal Medicine, Section of Neurology, Södersjukhuset, 11883 Stockholm, Sweden.ORCID 0009-0001-4719-6624
Aida GeamanuDepartment of Ophthalmology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Matei Popa CherecheanuDepartment of Cardiovascular Surgery, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Funding

Institutional programe "Publish not Perish", University of Medicine and Pharmacy Carol Davila 4192910
6 · The paper itself

Abstract

objectiveNeuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) are autoimmune-mediated central nervous system disorders distinguished by the presence of serum aquaporine-4 IgG antibody (AQP4-Ab). The clinical panel comprises severe optic neuritis (ON) and transverse myelitis, which can result in incomplete recovery and a high risk of recurrence.

methodsThis study aimed to evaluate the visual outcomes of three patients with severe acute ON in NMOSD that was non-responsive to intravenous methylprednisolone (IVMP), who received plasma exchange therapy (PLEX). We included three patients (P1, P2 and P3) with severe acute ON who had no improvement after IVMP treatment and were admitted to the ophthalmology department at the Emergency University Hospital Bucharest from January 2022 to September 2023. All three patients with ON were diagnosed in accordance with the criteria described by the Optic Neuritis Treatment Trial. All the subjects were experiencing their first attack.

resultsThe mean recruitment age was 35.3 ± 7.71. All patients were seropositive for the AQP4 antibody. All patients were tested for serum myelin oligodendrocyte glycoprotein (MOG) antibody but only one showed a positive test (P3). Lesions visible in orbital MRI indicated the involvement of retrobulbar, canalicular and/or intracranial segments. All three subjects had no response or incomplete remission after an IVMP protocol (5 days of 1000 mg intravenous methylprednisolone in sodium chloride 0.9%). The mean time from onset of optic neuritis to PLEX was 37.6 days. The PLEX treatment protocol comprised five cycles of plasma exchange treatment over 10 days, with a plasma exchange session every other day. An amount of 1 to 1.5 volumes of circulating plasma were dialyzed for 2-4 h. At 1 month after the completion of PLEX therapy, BCVA and VF parameters were improved in all three patients.

conclusionThe treatment of ON remains subject to debate and is somewhat controversial. Plasma exchange must be considered as a rescue therapy when IVMP is insufficient for AQP4-ON patients. This study revealed that PLEX treatment effectively improves the visual outcomes of patients experiencing their first attack of severe acute isolated ON after high-dose IVMP treatment. This study suggests that PLEX may be associated with improved visual outcomes in NMOSD acute optic neuritis.

Indexed as

neuromyelitis optica spectrum disorderoptic neuritisplasma exchange therapyvisual function

Identifiers

PMID38732279
PMCPMC11083380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.